DK0405537T3 - N-substituerede cycloalkyl og polycycloalkyl, alpha-substituerede Trp-Phe- og phenethylaminderivater - Google Patents

N-substituerede cycloalkyl og polycycloalkyl, alpha-substituerede Trp-Phe- og phenethylaminderivater

Info

Publication number: DK0405537T3
Authority: DK; Denmark
Prior art keywords: agents; substituted; alpha; treatment; phe
Prior art date: 1989-06-29

Application number

DK90112333T

Other languages

Danish (da)

English (en)

Inventor

Edward Roberts

David Christopher Horwell

Martyn Clive Pritchard

Reginald Stewart Richardson

Julian Aranda

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-06-29

Filing date

1990-06-28

Publication date

2005-01-10

1990-06-28 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2005-01-10 Application granted granted Critical

2005-01-10 Publication of DK0405537T3 publication Critical patent/DK0405537T3/da

Links

IMMPMHKLUUZKAZ-WMZOPIPTSA-N Trp-Phe Chemical class C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(O)=O)C1=CC=CC=C1 IMMPMHKLUUZKAZ-WMZOPIPTSA-N 0.000 title abstract 2
BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical class NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 title 1
125000005592 polycycloalkyl group Polymers 0.000 title 1
239000003795 chemical substances by application Substances 0.000 abstract 2
230000001684 chronic effect Effects 0.000 abstract 2
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
102100021022 Gastrin Human genes 0.000 abstract 1
108010052343 Gastrins Proteins 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
239000000164 antipsychotic agent Substances 0.000 abstract 1
229940005529 antipsychotics Drugs 0.000 abstract 1
239000003699 antiulcer agent Substances 0.000 abstract 1
239000002249 anxiolytic agent Substances 0.000 abstract 1
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 abstract 1
229960003920 cocaine Drugs 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 abstract 1
229960003529 diazepam Drugs 0.000 abstract 1
210000004211 gastric acid Anatomy 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
229960002715 nicotine Drugs 0.000 abstract 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Biophysics (AREA)
Hematology (AREA)
Obesity (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Anesthesiology (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Indole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Peptides Or Proteins (AREA)
Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

DK90112333T 1989-06-29 1990-06-28 N-substituerede cycloalkyl og polycycloalkyl, alpha-substituerede Trp-Phe- og phenethylaminderivater DK0405537T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US37432789A	1989-06-29	1989-06-29
US42248689A	1989-10-16	1989-10-16
US53081190A	1990-06-05	1990-06-05

Publications (1)

Publication Number	Publication Date
DK0405537T3 true DK0405537T3 (da)	2005-01-10

Family

ID=27409174

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK90112333T DK0405537T3 (da)	1989-06-29	1990-06-28	N-substituerede cycloalkyl og polycycloalkyl, alpha-substituerede Trp-Phe- og phenethylaminderivater

Country Status (17)

Country	Link
EP (2)	EP0479910A1 (de)
JP (1)	JP2972331B2 (de)
KR (2)	KR0167315B1 (de)
CN (1)	CN1049165A (de)
AT (1)	ATE275546T1 (de)
AU (1)	AU644088B2 (de)
CA (2)	CA2060652C (de)
DE (1)	DE69034162T2 (de)
DK (1)	DK0405537T3 (de)
ES (1)	ES2229202T3 (de)
FI (1)	FI106197B (de)
IE (1)	IE902347A1 (de)
IL (1)	IL94903A0 (de)
NO (1)	NO301831B1 (de)
NZ (1)	NZ234264A (de)
PT (1)	PT94543B (de)
WO (1)	WO1991000274A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5162336A (en) *	1990-06-21	1992-11-10	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Tetrahydro-pyrido-indoles as cholecystokinin and gastrin antagonists
US5340825A (en) *	1990-08-31	1994-08-23	Warner-Lambert Company	Pro drugs for CCK antagonists
US5593967A (en) *	1990-08-31	1997-01-14	Warner-Lambert Company	Cholecystokinin antagonists, their preparation and therapeutic use
US5244915A (en) *	1990-08-31	1993-09-14	Warner-Lambert Company	Amico acid derivatives cyclized at the c-terminal
CA2088195A1 (en) *	1990-08-31	1992-03-01	David C. Horwell	Cholecystokinin antagonists, their preparation and therapeutic use
CA2088980C (en) *	1990-08-31	2002-04-16	David C. Horwell	Pro-drugs for cck antagonists
US5264420A (en) *	1990-09-27	1993-11-23	Merck & Co., Inc.	Fibrinogen receptor antagonists
EP0668770A1 (de) *	1991-04-24	1995-08-30	Warner-Lambert Company	Alpha-substituierte polypeptide und therapeutischer aktivität
FI934894L (fi) *	1991-05-07	1993-11-05	Merck & Co Inc	Fibrinogenreceptorantagonister
CA2110986A1 (en) *	1991-07-12	1993-01-21	Geoffrey Neil Woodruff	Cholecystokinin antagonists useful in the treatment of panic attacks
US5153191A (en) *	1991-08-20	1992-10-06	Warner-Lambert Company	Cholecystokinin antagonists useful for treating depression
US5217957A (en) *	1991-08-20	1993-06-08	Warner-Lambert Company	Cholecystokinin antagonists useful for treating depression
US5389631A (en) *	1991-10-29	1995-02-14	Merck & Co., Inc.	Fibrinogen receptor antagonists
US5272158A (en) *	1991-10-29	1993-12-21	Merck & Co., Inc.	Fibrinogen receptor antagonists
DE4137490A1 (de) *	1991-11-14	1993-05-19	Goedecke Ag	Synthese von tricyclo(3.3.1.13,7)dec-2.yl(r-(r,r))-3- (1h-indol-3-yl-methyl)-3-methyl-4,9-dioxo- 7,11-diphenyl-10-oxa-2,5,8-triaza-undecanat
US6492531B1 (en)	1992-02-18	2002-12-10	Warner-Lambert Company	Method of treating cognitive disorders
GB9316722D0 (en) *	1993-08-12	1993-09-29	Black James Foundation	Bicyclo (2.2.2)octane derivatives
WO1993016982A1 (en) *	1992-02-20	1993-09-02	James Black Foundation Limited	Bicyclo[2.2.2.]octane derivatives as cholestocystokinin inhibitors
US5514683A (en) *	1992-02-20	1996-05-07	James Black Foundation Limited	Bicyclo 2,2,2!octane derivatives
US5227490A (en) *	1992-02-21	1993-07-13	Merck & Co., Inc.	Fibrinogen receptor antagonists
EP0655053B1 (de) *	1992-06-19	1997-09-03	James Black Foundation Limited	Bicyclooctan und bicycloheptan derivate
US5380872A (en) *	1992-07-14	1995-01-10	Glaxo Inc.	Modulators of cholecystokinin
US5922681A (en) *	1992-09-14	1999-07-13	Warner-Lambert Company	Endothelin antagonists
EP0667773A4 (de) *	1992-10-14	1996-09-25	Merck & Co Inc	Fibrinogen-rezeptor-antagonisten.
US5358956A (en) *	1992-10-14	1994-10-25	Merck & Co., Inc.	Fibrinogen receptor antagonists
US5340798A (en) *	1992-10-14	1994-08-23	Merck & Co., Inc.	Fibrinogen receptor antagonists
AU675680B2 (en) *	1992-10-14	1997-02-13	Merck & Co., Inc.	Fibrinogen receptor antagonists
CA2150550A1 (en) *	1992-12-01	1994-06-09	Melissa S. Egbertson	Fibrinogen receptor antagonists
FR2700540B1 (fr) *	1993-01-15	1995-02-17	Irj	alpha-méthyl-(R)-tryptophyl-arylcycloalkylalkylamides ligands aux récepteurs des gastrines, leur préparation et leur utilisation en thérapeutique.
US5441952A (en) *	1993-04-05	1995-08-15	Merck & Co., Inc.	Fibrinogen receptor antagonists
US5334596A (en) *	1993-05-11	1994-08-02	Merck & Co., Inc.	Fibrinogen receptor antagonists
US5397791A (en) *	1993-08-09	1995-03-14	Merck & Co., Inc.	Fibrinogen receptor antagonists
US5821241A (en) *	1994-02-22	1998-10-13	Merck & Co., Inc.	Fibrinogen receptor antagonists
WO1995032949A1 (en) *	1994-05-27	1995-12-07	James Black Foundation Limited	Gastrin and cck antagonists
US5719144A (en) *	1995-02-22	1998-02-17	Merck & Co., Inc.	Fibrinogen receptor antagonists
US5852045A (en) *	1995-10-19	1998-12-22	Merck & Co., Inc.	Fibrinogen receptor antagonists
US5789421A (en) *	1995-10-26	1998-08-04	Merck & Co., Inc.	Fibrinogen receptor antagonist
US5780480A (en) *	1996-02-28	1998-07-14	Merck & Co., Inc.	Fibrinogen receptor antagonists
US5889023A (en) *	1996-05-10	1999-03-30	Merck & Co., Inc.	Fibrinogen receptor antagonist
US5981584A (en) *	1997-02-06	1999-11-09	Merck & Co., Inc.	Fibrinogen receptor antagonist prodrugs
RU2227144C2 (ru) *	2001-11-15	2004-04-20	Научно-исследовательский институт фармакологии РАМН	Замещенные триптофансодержащие дипептиды с холецистокининонегативной или холецистокининопозитивной активностью
US7375093B2 (en)	2002-07-05	2008-05-20	Intrexon Corporation	Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7880001B2 (en)	2004-04-29	2011-02-01	Abbott Laboratories	Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US8415354B2 (en)	2004-04-29	2013-04-09	Abbott Laboratories	Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20100222316A1 (en)	2004-04-29	2010-09-02	Abbott Laboratories	Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
KR101496190B1 (ko)	2005-01-05	2015-02-26	애브비 인코포레이티드	11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제로서의 아다만틸 유도체
US8198331B2 (en)	2005-01-05	2012-06-12	Abbott Laboratories	Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
CA2594116A1 (en)	2005-01-05	2006-07-13	Abbott Laboratories	Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20090192198A1 (en)	2005-01-05	2009-07-30	Abbott Laboratories	Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
JP5736098B2 (ja)	2007-08-21	2015-06-17	アッヴィ・インコーポレイテッド	中枢神経系障害を治療するための医薬組成物
JP7086171B2 (ja) *	2017-04-10	2022-06-17	ザリージェンツオブザユニヴァシティオブミシガン	共有結合性小分子ｄｃｎ１阻害物質およびそれを使用する治療方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4482567A (en) *	1982-10-07	1984-11-13	Research Foundation For Mental Hygiene, Inc.	N-hexanoyl to n-heptadecanoyl 5-hydroxy tryptophan-5-hydroxytryptophanamides and use as analgesics
US4757151A (en) *	1985-11-14	1988-07-12	Warner-Lambert Company	2-substituted-[2-substituted-amino]-N-arylalkyl-3-[indol-3-yl]
US4814463A (en) *	1985-12-31	1989-03-21	Biomeasure, Inc.	CCK antagonists
JP5614660B2 (ja)	2012-07-19	2014-10-29	株式会社デンソー	燃料性状センサ

1990
- 1990-06-27 NZ NZ234264A patent/NZ234264A/xx unknown
- 1990-06-28 ES ES90112333T patent/ES2229202T3/es not_active Expired - Lifetime
- 1990-06-28 DK DK90112333T patent/DK0405537T3/da active
- 1990-06-28 IL IL94903A patent/IL94903A0/xx unknown
- 1990-06-28 IE IE234790A patent/IE902347A1/en unknown
- 1990-06-28 CA CA002060652A patent/CA2060652C/en not_active Expired - Fee Related
- 1990-06-28 AU AU59628/90A patent/AU644088B2/en not_active Ceased
- 1990-06-28 KR KR1019910702001A patent/KR0167315B1/ko not_active Expired - Fee Related
- 1990-06-28 AT AT90112333T patent/ATE275546T1/de not_active IP Right Cessation
- 1990-06-28 DE DE69034162T patent/DE69034162T2/de not_active Expired - Fee Related
- 1990-06-28 WO PCT/US1990/003553 patent/WO1991000274A1/en not_active Ceased
- 1990-06-28 EP EP90911185A patent/EP0479910A1/de active Pending
- 1990-06-28 JP JP2510126A patent/JP2972331B2/ja not_active Expired - Fee Related
- 1990-06-28 EP EP90112333A patent/EP0405537B1/de not_active Expired - Lifetime
- 1990-06-28 CA CA002344707A patent/CA2344707C/en not_active Expired - Fee Related
- 1990-06-29 CN CN90106804A patent/CN1049165A/zh active Pending
- 1990-06-29 PT PT94543A patent/PT94543B/pt not_active IP Right Cessation
1991
- 1991-12-20 FI FI916060A patent/FI106197B/fi not_active IP Right Cessation
- 1991-12-27 NO NO915122A patent/NO301831B1/no not_active IP Right Cessation
1998
- 1998-06-26 KR KR1019980704957A patent/KR0180539B1/ko not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NO915122L (no)	1992-02-27
CA2060652C (en)	2001-08-21
NO301831B1 (no)	1997-12-15
KR0167315B1 (ko)	1999-01-15
EP0405537B1 (de)	2004-09-08
JP2972331B2 (ja)	1999-11-08
CA2344707C (en)	2002-07-30
IE902347L (en)	1990-12-29
DE69034162D1 (de)	2004-10-14
NO915122D0 (no)	1991-12-27
KR0180539B1 (en)	1999-05-01
JPH04506079A (ja)	1992-10-22
PT94543A (pt)	1991-03-20
IL94903A0 (en)	1991-04-15
FI916060A0 (fi)	1991-12-20
WO1991000274A1 (en)	1991-01-10
EP0405537A1 (de)	1991-01-02
CA2060652A1 (en)	1990-12-30
KR920702678A (ko)	1992-10-06
CA2344707A1 (en)	1991-01-10
FI106197B (fi)	2000-12-15
IE902347A1 (en)	1991-01-16
PT94543B (pt)	1997-04-30
ES2229202T3 (es)	2005-04-16
DE69034162T2 (de)	2005-09-22
AU644088B2 (en)	1993-12-02
CN1049165A (zh)	1991-02-13
EP0479910A1 (de)	1992-04-15
AU5962890A (en)	1991-01-17
ATE275546T1 (de)	2004-09-15
NZ234264A (en)	1993-05-26

Publication	Publication Date	Title
ATE275546T1 (de)	2004-09-15	N-substituierte cycloalkyl- und polycycloalkyl- alpha-substituierte trp-phe- und phenethylaminderivate
HUT48455A (en)	1989-06-28	Process for producing stabilized pharmaceutical compositions containing dipeptide derivatives
EP0285008A3 (en)	1990-06-06	The use of buspirone for preparing a pharmaceutical composition for the treatment of alcohol abuse
NO176101C (no)	1995-02-01	Analogifremgangsmåte for fremstilling av terapeutisk aktive N-(3-hydroksy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran eller dihydrobenzodioksin)karboksamidderivater
NO157145C (no)	1988-01-27	Analogifremgangsmaate til fremstilling av terapeutisk aktive n-glykosylerte karboksylsyreamidderivater.
DK0546108T3 (da)	2002-02-18	Pro-drugs for CCK-antagonister
HUT52040A (en)	1990-06-28	Process for producing diaryl-derivatives and pharmaceutical compositions containing them
BG101220A (bg)	1997-08-29	N-заместени 3-азабицикло(3.2.0) хептанови производни, метод за получаване и използването им
DK218189D0 (da)	1989-05-03	Fumarsyrekonjugat og farmaceutisk praeparat indeholdende en saadan forbindelse
HU901095D0 (en)	1991-09-30	Process for producing compound reducing extraction of gastric acid and pharmaceutical preparative containing said compound
NO900342D0 (no)	1990-01-24	Fremgangsmaate for fremstilling av terapeutisk aktive 3-fenyl-5,6-dihydrobenz(c)acridin-7-carboxylsyrer og beslektede forbindelser.
FR2655043B1 (fr)	1992-02-07	Nouveaux derives du thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
NO891071L (no)	1989-09-15	Fremgangsmaate for fremstilling av 4,5,6,7-tetrahydro-isotiazolo(4,5-c)-pyridinderivater og isomere.
ES2126577T3 (es)	1999-04-01	Analogos alquilidenicos de 1'-aminoespiro(isoquinolino-4(1h),3'-pirrolidino)-1,2',3,5'(2h)-tetronas utiles como inhibidores de la aldosa reductasa in vivo.
FR2647785B1 (fr)	1991-09-06	Nouveaux derives de la pyrrolidone, leur procede de preparation et les compositions pharmaceutiques les renfermant
RU92016209A (ru)	1996-03-20	Бензофуранилимидазольные производные, способ их получения и терапевтические композиции, содержащие названные производные
KR940021524A (ko)	1994-10-19	1,2,5,6-테트라하이드로피리딘 유도체와 이의 제조 방법 및 치료시 이의 이용방법
NZ220539A (en)	1989-04-26	1,4-dihydropyridine derivatives and pharmaceutical compositions
PY0101652A (es)	2001-12-03	Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
DK0437645T3 (da)	1995-05-01	Imidazolylpropylguanidinderivat, fremgangsmåde til fremstilling deraf og lægemidler indeholdende denne forbindelse